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Abstract: Purpose: This study investigates the feasibility of personalizing radiotherapy prescription
schemes (treatment margins and fractional doses) for glioblastoma (GBM) patients and their
potential benefits using a proliferation and invasion (PI) glioma model on phantoms. Methods
and Materials: We propose a strategy to personalize radiotherapy prescription schemes by simulating
the proliferation and invasion of the tumor in 2D according to the PI glioma model. We demonstrate
the strategy and its potential benefits by presenting virtual cases, where the standard and personalized
prescriptions were applied to the tumor. Standard prescription was assumed to deliver 46 Gy in
23 fractions to the initial, gross tumor volume (GTV1) plus a 2 cm margin and an additional 14 Gy
in 7 fractions to the boost GTV2 plus a 2 cm margin. The virtual cases include the tumors with a
moving velocity of 0.029 (slow-move), 0.079 (average-move), and 0.13 (fast-move) mm/day for the
gross tumor volume (GTV) with a radius of 1 (small) and 2 (large) cm. For each tumor size and
velocity, the margin around GTV1 and GTV2 was varied between 0–6 cm and 1–3 cm, respectively.
Equivalent uniform dose (EUD) to normal brain was constrained to the EUD value obtained by using
the standard prescription. Various linear dose policies, where the fractional dose is linearly decreasing,
constant, or increasing, were investigated to estimate the temporal effect of the radiation dose on
tumor cell-kills. The goal was to find the combination of margins for GTV1 and GTV2 and a linear
dose policy, which minimize the tumor cell-surviving fraction (SF) under a normal tissue constraint.
The efficacy of a personalized prescription was evaluated by tumor EUD and the estimated survival
time. Results: The personalized prescription for the slow-move tumors was to use 3.0–3.5 cm margins
for GTV1, and a 1.5 cm margin for GTV2. For the average- and fast-move tumors, it was optimal to
use a 6.0 cm margin for GTV1 and then 1.5–3.0 cm margins for GTV2, suggesting a course of whole
brain therapy followed by a boost to a smaller volume. It was more effective to deliver the boost
sequentially using a linearly decreasing fractional dose for all tumors. Personalized prescriptions led
to surviving fractions of 0.001–0.465% compared to the standard prescription, and increased the tumor
EUDs by 25.3–49.3% and estimated survival times by 7.6–22.2 months. Conclusions: Personalizing
treatment margins based on the measured proliferative capacity of GBM tumor cells can potentially
lead to significant improvements in tumor cell kill and related clinical outcomes.
Keywords: radiotherapy treatment planning; glioblastoma; mathematical model
1. Introduction
Glioblastoma is highly heterogeneous, where different cells within the tumor respond to different
types of therapy, leading to a treatment regimen involving multiple modalities [1]. Despite aggressive
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treatment with surgical resection and chemo-radiation, the prognosis remains poor with short median
survival of less than 15 months with radiotherapy plus concomitant and adjuvant Temozolomide [2],
and there has not been a dramatic improvement in survival over the last several decades [3].
Studies show that the extent of the surgical resection is an important prognostic factor in
Glioblastoma Multiforme (GBM) [4]. However, most patients, including those who received the
most radical surgical excisions, die of recurrent tumors [5]. Ogura et al. analyzed the locations of
recurrent tumors for 21 patients [6]. Their study showed that initial recurrence occurred centrally
at first (67% of the total patients) but distant recurrences were also observed in 19% of the patients.
Cumulative recurrence patterns showed distant recurrences in the majority of the patients (88%).
These clinical observations suggest that tumor cells spread throughout the brain. Swanson et al.
published a mathematical model to describe the spatio-temporal dynamics of glioma cells using a
reaction-diffusion equation [7]. Their model uses patient-specific, net rates of proliferation and invasion
obtained from serial Magnetic Resonance Imaging (MRIs) as input parameters to describe how quickly
the tumor grows and migrates in the spatiotemporal space. Therefore, their model predicts the tumor
(both gross and microscopic disease) growth beyond what can be seen with current imaging technology.
The prediction of tumor growth using their model also agrees with the clinical observation that glioma
cells invade into normal brain. Therefore, the optimal extent of the treatment volume may affect
clinical outcomes.
The standard treatment includes maximal safe resection followed by concurrent chemotherapy
and radiotherapy to the resection cavity with a margin to eradicate the remaining tumor cells [8].
Radiation therapy of 60 Gy in 30 fractions is given either to one tumor volume or in two phases, where
46 Gy is given to a large volume and an additional 14 Gy to a reduced volume. The initial target volume
consists of the gross tumor volume (GTV1), which is defined by either the T2 or Fluid-Attenuated
Inversion Recovery (FLAIR) signal on the post-operative MRI scan, plus a margin. The boost target
volume (GTV2) is based on the contrast-enhanced, T1 MRI scan, plus a margin [6]. A variable margin
around GTV1 and GTV2 is currently used to define the clinical target volumes for each phase reflecting
the difficulty in determining the exact extent of the tumor cells. Ghose et al. surveyed the variability in
the practice patterns of Canadian radiation oncologists treating GBM [9]. They reported a significant
variation in the margins used, ranging from 0.5 cm to 3.0 cm, with some of them using more than one
standard margin. Multiple studies indicate that there is a lack of consensus in the most appropriate
target volume to be treated [9–11].
The purpose of this study is to investigate the feasibility of personalizing prescription schemes
using a tumor growth model, which includes patient-specific parameters, and to estimate their potential
benefits on clinical outcome. Specifically, we assume that the spatiotemporal dynamics of the tumor
follow the proliferation and invasion (PI) glioma model described in [12]. In this study, the prescription
scheme is defined by the margins around GTV1 and GTV2, and the prescription dose for GTV1, while
keeping the total dose for GTV2 to 60 Gy. We also investigated the temporal effect of the radiation
on the tumor damage by linearly increasing or decreasing a fractional dose, and delivering a boost
phase either concurrently or sequentially. The goal is to find the most effective treatment margins and
temporal dose policy in killing tumor-cells without increasing the generalized equivalent uniform dose
(gEUD) to normal brain compared to the current standard-of-care. The efficacy of the personalized
prescription schemes was evaluated by comparing the cell-surviving fraction (SF), tumor EUD, and
the estimated survival time with those of the standard-of-care.
2. Methods and Materials
2.1. Prescription Geometry
A standard prescription to treat GBM was assumed to deliver a total dose of 60 Gy (=TD2) in two
phases, with 46 Gy (=TD1) being delivered in 23 fractions in the initial phase to GTV1 plus a 2 cm
margin followed by a boost of 14 Gy in 7 fractions to GTV2 plus a 2 cm margin (Figure 1) [11].
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Figure 1. Prescription geometry. For the standard prescription, TD1 = 46 Gy, TD2 = 60 Gy, and
1 = M2 = 2 cm.
2.2. Tumor Growth Simulation Using a PI Glioma Model
We used the spatio-temporal model of the tumor proliferation and invasion under the effect of
radiotherapy as presented in [12]. Let D be a diffusion coefficient, and s be the length of a radiotherapy
session. Let ρ and k be the parameters related to the rate of cell proliferation and the carrying capacity
of the tissue, respectively. Then the tumor dynamics under radiotherapy can be modeled as follows:
∂c
∂t
= ∇(D∇c)︸ ︷︷ ︸
Net dispersion
ρc(1 c/k)︸ ︷︷ ︸
Net proliferation
− Rc/s︸ ︷︷ ︸
Net cell-kills
by radiation
(1)
where c = c(x, t) is the glioma cell concentration and R = R(x, t) is the cell loss due to radiotherapy
at location x and time t. Equation (1) describes the rate of change in the glioma cell concentration at
any given point in the brain in terms of the tumor dispersion velocity and proliferation rate, which
vary among different patients and are measurable from two or more MRIs taken at different times.
The linear quadratic (LQ) cell-survival model [13] gives the loss of glioma cells during radiotherapy
as follows:
R(x, t) =
 1− exp
[
−α
(
dt(x) +
dt (x)
2
α/β
)]
: during radiotherapy
0 : between fractions,
(2)
where dt (x) is th dose administered at time t to location x, and α and β are tissue specific
radio-sensitivity p rameters. We used the two-dimensional finite difference method to approximately
solve for c(x, y; t) in Equation (1).
The tumor volume was simulated using Equation (1) ith the following parameters as in [3]:
ρ = 0.012/d y, α = 0.035 Gy, α/β = 10 Gy, and k = 109/cm3. Swanson et al. reported in [14] that the
measured v lues of D from serial MRIs for 70 patients ranged fr m 0.24 to 35.92 mm2/d y (mean
10.52, median 9.83 mm2/day) and used Fisher’s approximation to calcul te an approximate radial
velocity of expansion of the edge of a tumor (v =
√
2 ρD). The velocity (v) ranged between 0.0118 and
0.1438 mm/day. Based on this report, we used three values of D = 0.017, 0.13, and 0.34 mm/day to
characterize slow-, average-, an fast-move tumors.
Swanson et al. hypothesized that the ci cumference of the T2 MR yper-intense area (GTV1)
and T1-Gd MR hyper-intense area (GTV2) represent 16% and 80% of the maximum tumor cell
concentration [15], respectively. We studied two different GTV2 sizes: GTV1 was obtained when
the radius of GTV2 reached 1.0 and 2.0 cm from the initial condition of c0 (x0, y0; 0) = L3e−100(x
2
0 + y20),
where L is the length of the computational domain [12]. The corresponding radius of GTV1 was
recorded for each GTV2 (Table 1).
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Table 1. Tumor size and moving velocity used in this study.
Moving Velocity (mm/day) GTV1 Radius (cm) GTV2 Radius (cm)
0.029
(slow-move)
1.7 1.0 (small)
2.7 2.0 (large)
0.079
(average-move)
2.7 1.0 (small)
4.2 2.0 (large)
0.13
(fast-move)
2.7 1.0 (small)
5.2 2.0 (large)
Gross tumor volume (GTV1) was simulated using the parameters of proliferation rate (ρ = 0.012 day−1) and carrying
capacity (k = 109 cm−3) for each size of GTV2.
We simulated the tumor with and without modeling the resection cavity. The resection cavity
was modeled by setting the number of tumor cells inside GTV2 to zero.
2.3. Prescription Scheme Variables
The goal is to find the treatment margins around GTV1 and GTV2 (i.e., M1 and M2) as well
as TD1 delivered to GTV1 + M1, which leads to the minimum total number of tumor cells after 30
fractions. The margins M1 and M2 were chosen from the sets {0, 0.5, 1.0, · · · , 6.0} and {1.0, 1.5, 2.0,
2.5, 3.0}, respectively. In our simulation, TD2 was fixed at 60 Gy. TD1 was constrained such that the
generalized equivalent uniform dose (gEUD) of normal brain equals the gEUD resulting from the
standard prescription. This means that the treatment with a larger margin is feasible only with a
smaller dose to ensure that the toxicity of the non-standard prescription scheme on the normal brain
does not exceed the toxicity from the standard prescription. Normal brain gEUD was calculated as
follows [16]:
gEUD = (f1TD1a + f2TD2a)−a, (3)
f1 + f2 ≤ 1, TD2 = 60 Gy,
where f1 and f2 are the fractional areas irradiated to TD1 and TD2, respectively, and a is a tissue-specific
sensitivity parameter. The sum of f1 and f2 would be less than 1 only if the irradiated area of the
standard prescription is larger than the prescription scheme investigated, i.e., there is a fractional area
(1–f1 –f2) with zero dose. TD1 is obtained by constraining gEUD of the normal brain to be the same as
the standard prescription:
(f1standard 46a + f2standard 60a)−a = (f1non-standard TD1a + f2non-standard 60a)−a (4)
Therefore, TD1 is a function of M1, M2, and the radii of GTV1 and GTV2. In this study, we used
a = 5 for normal brain [15,17]. We also varied a between 3 and 7 to investigate the sensitivity of the
optimal solutions on a. To examine the temporal effect of the radiation dose, five different, linear dose
policies (P1–P5) have been implemented as shown in Figure 2. The sum of the fractional doses is fixed
at 60 Gy. P3 represents the current, constant dose policy, in which the fractional dose is fixed at 2 Gy.
Linearly increasing (P1/P2) or decreasing dose (P4/P5) policies were implemented with an initial
dose of 1.0/1.5 Gy for P1/P2 and 2.5/3.0 Gy for P4/P5 (Figure 2). We ignored the fractionation effects
on the normal brain because the linear dose policies investigated in this study result in a clinically
insignificant difference in the biologically effective dose (BED) using α/β = 3 Gy, i.e., 100, 100.9, and
103.4 Gy for P3, P2/P4, and P1/P5, respectively.
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2.4. Evaluation Criteria
The efficacy of each non-standard prescription sche e as evaluated by co paring the tu or
cell-surviving fraction (SF) after 30 fractions relative to the SF that resulted fro the standard
prescription. In addition, the tu or E of the personalized prescription relative to the E fro
the standard prescription as calculated. The higher the E is, the higher the tu or cell-kill that is
achieved. Let SF and SF0 be the tu or cell-surviving fraction after the treat ent course using the
personalized prescription and the standard prescription, respectively. Si ilarly, let EUD* and E 0
be the E fro the personalized and the standard prescription, respectively. Then the surviving
fraction can be ritten as:
SF∗ = exp[−αEUD β(EUD )2/N],
SF0 = exp[−αEUD β(EUD /N],
where N = 30 fractions. Therefore, EUD* as a function of EUD0 is given by:
EUD∗ =
(
N
2β
)(
−α+
√
α2 +
4β
N
(
αEUD0 +
β
(
EUD0
)2
N
− ln
(
SF∗
SF0
)))
. (5)
EUD0 was calculated using Equation (3) with a = −10 for the tumor [17].
We also estimated the survival times for the standard and personalized prescriptions. Swanson
et al. showed that their PI glioma model predicts the actual survival time by simulating the tumor
growth until it reaches its fatal radius of 3 cm [18], which they used as an indicator of the interval to
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death. We let the tumor grow after the course of radiotherapy and measured the time required for
GTV2 to reach a radius of 3 cm for the standard and personalized prescription schemes, respectively.
3. Results
Personalized prescription schemes were not affected by the following parameters: (i) modeling
resection cavity in the tumor growth simulation (ii) radiobiological parameters (α/β) used in the LQ
cell-survival model, and (iii) the EUD parameter, a. Therefore, all the results are presented in this
section using a = 5 for the normal brain and α/β = 10 Gy for the tumor without the modeling resection
cavity. In summary, Table 2 shows the personalized prescription scheme for each tumor size and
velocity studied, which leads to the maximum cell-kills in the simulation. Table 3 shows the tumor
EUD and the expected survival that results from using these personalized prescription schemes in
Table 2. The percentage improvements are relative to the results from using the standard prescription.
3.1. Sequential and Concurrent Boost
Tumor SF for the personalized prescription was normalized to that for the standard prescription
using:
Personalized SF∗(%) =
SF using personalized M1, M2, and TD1
SF using the standard prescription
× 100. (6)
Personalized SF (P-SF) using the sequential boost was 18.3–61.3% lower than the P-SF using the
concurrent boost for all cases except for the fast-move, large tumor. In this case, the concurrent boost
P-SF was 41.4% lower than the sequential boost P-SF.
For the sequential boost, the personalized M1 ranged from 3.0–6.0 cm, and M2 was 1.5 cm for
all tumors except for the fast-move, large tumor. The corresponding TD1 ranged between 20.7 and
45.6 Gy. A linearly decreasing dose policy P5, i.e., a larger fraction size upfront, led to the smallest SF
for all tumor sizes and velocities. P-SF for all tumors studied was 0.001–0.465% of the SF that resulted
from the standard prescription (Table 2).
3.2. Stationary Fractional Dose Policy
To evaluate if the constant fractional dose policy (P3) is clinically equivalent to the personalized
dose policy, we compared SF using P3 to the standard prescription and to P5 (with M1, M2, and TD1
being fixed to their personalized values for both P3 and P5). For the different tumor characteristics
(sizes and velocities), the SF using P3 relative to the SF using the standard prescription varied from
0.001–0.491% (sequential boost) and 0.002–0.330% (concurrent boost). Relative to P-SF, the stationary
dose policy (P3) resulted in a higher SF: 105.7–218.8% (sequential) and 100.4–136.9% (concurrent).
3.3. Comparison of EUD and Estimated Survival Time
We computed EUD of the tumor using the personalized prescription (Table 2) relative to that
with the standard prescription. (Note that EUD >100% indicates superiority of the personalized
prescription; this is the opposite of the P-SF.) The EUD using the personalized prescription was
123.8–149.3% and 125.3–146.5% of the EUD from the standard prescription for the sequential and
concurrent boost, respectively. The EUD using P3 and personalized M1, M2, and TD1 was 123.6–147.5%
and 125.3–146.1% of the EUD resulting from the standard prescription for the sequential and concurrent
boost, respectively. Therefore, the difference in the tumor EUD between P5 and P3 with a sequential
boost is less than 3% for all tumors if M1, M2, and TD1 are fixed at their personalized values.
To calculate the effects of radiation therapy on the subsequent growth of the tumor, and hence the
length of survival according to the model described in [7], the tumor cell distribution at the end of
30 fractions for each specific prescription was used as the starting point for calculating post-therapy
tumor growth and spread. Then tumor growth was calculated according to Equation (1) with R = 0
(no radiation), and the time in months it took for the tumor to reach its fatal radius of 3.0 cm was
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determined. For the post-radiotherapy tumor growth, serial MRIs were not available to measure
the patient-specific ρ/D. Therefore, we assumed that ρ was increased to 0.020/day to calibrate the
survival time for the average-move tumors treated with the standard prescription to be approximately
19 months [19]. With this assumption, the optimal prescription led to a 7.6–22.2 months longer survival
time than the standard prescription (Table 3).
Table 2. Personalized prescription schemes.
Velocity (mm/day) GTV2 Radius(cm) P-SF (%) P-M1 (cm)
P-TD1
(Gy) P-M2 (cm)
P-Boost
Delivery
P-Dose
Policy
0.029
(slow-move)
1.0 0.021 3.0 45.6 1.5 Sequential P5
2.0 0.048 3.5 43.7 1.5 Sequential P5
0.079
(average-move)
1.0 0.001 6.0 (max) 37.0 1.5 Sequential P5
2.0 0.001 6.0 (max) 38.3 1.5 Sequential P5
0.13
(fast-move)
1.0 0.001 6.0 (max) 37.0 1.5 Sequential P5
2.0 0.328 6.0 (max) 32.9 2.5 Concurrent P5
Personalized (P-) treatment margins (M1 for GTV1 and M2 for GTV2), total dose in the initial phase (TD1), and dose
policy are shown for each tumor studied. The tumor cell-surviving fraction (SF) using the personalized prescription
is shown as a percentage of SF obtained from the standard prescription (M1 = M2 = 2 cm, TD1 = 46 Gy).
Table 3. Efficacy of personalized prescriptions.
Velocity (mm/day) GTV2Radius (cm)
P-Tumor
EUD (%)
Std. Estimated Survival
Time (Months)
P-Estimated Survival
Time (Months)
0.029
(slow-move)
1.0 134.3 53.5 62.5
2.0 130.4 47.4 57.3
0.079
(average-move)
1.0 149.3 20.6 36.9
2.0 148.0 17.7 33.2
0.13
(fast-move)
1.0 147.9 19.6 41.8
2.0 123.8 10.2 17.9
Personalized (P-) equivalent uniform dose (EUD) of the tumor relative to EUD using the standard prescription
(=100%) and estimated survival time in months. Standard (Std.) survival time was estimated by calibrating a
proliferation parameter to match with the published data [19].
4. Discussion
In the past, many clinical trials have been conducted for the treatment of GBMs, but there has
been little progress. The failures can occur at the edges of the radiation field and even in more distant
locations in the brain. These patterns of failure have led to a current Phase II clinical trial to estimate
the efficacy of low-dose whole brain irradiation (0.15 Gy per fraction to whole brain and 1.85 Gy per
fraction to GTV for 30 fractions) to reduce the distant recurrence rate [20]. The growing understanding
of tumor dynamics and proliferation, as exemplified by Swanson’s model [7], provides new impetus
for exploring improved treatment strategies.
Given the expense and time needed to carry out clinical trials, and given the good correspondence
of the models with clinical data, we have an opportunity to provide some critical insight into some
promising future directions. The purpose of our current study is to investigate the feasibility of
personalizing the radiotherapy prescription scheme based on the individual tumor characteristics to
increase the efficacy of tumor cell-kills using radiation. We utilized patient-specific, glioma dynamics
developed and clinically validated by Swanson et al. [7]. Using their model, Rockne et al. studied
the effect of the fractionation schedules, dose distribution, and radiation sensitivity parameters [12].
They concluded that hypofractionation is more effective than hyperfractionation.
Applying this model allows us to simulate the effects of tumor growth and spread of some
prescription variables: treatment margins, fractional doses, and timing of boost irradiation. By applying
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dose limits on normal tissue and tumors that are currently accepted, we have limited our simulation to
clinically feasible values. We limited the total prescription dose to 60 Gy since dose escalation beyond
that point was not proven to be efficacious in improving clinical outcomes [21]. Our results indicate
that individual tumor characteristics (velocity of growth, size) make a difference in the prescription
scheme that leads to the minimum tumor SF (or equivalently maximum tumor EUD).
According to our study, the most significant factors in improving the treatment efficacy are
the margins around GTV1 and GTV2. Although a linearly decreasing dose policy (P5), i.e., a larger
fractional dose upfront, was found to be more effective than the constant fractional dose policy (P3),
the difference from P3 was less than 3% in the tumor EUD. A sequential boost also leads to a lower
SF than a concurrent boost for almost all tumor sizes and velocities; however, the EUD using the
sequential boost was larger than the EUD using the concurrent boost by no more than 4%. For the
average- and fast-move tumors, the personalized margin in the initial phase was 6.0 cm, which was the
maximum margin used in this study. This suggests that whole brain radiotherapy in the initial phase
to 20.7–38.3 Gy followed by the focal radiation to GTV2 plus 1.5 cm margin to 60 Gy (except for the
fast-move, large tumors, where the optimal M2 is 3.0 cm) may be beneficial for patients with average-
and fast-move tumors. On the other hand, it was found to be effective to use 3.0 and 3.5 cm margins in
the initial phase to 43.7–45.6 Gy for slow-move, small, and large tumors, respectively, and then to use a
1.5 cm margin in the boost phase. Wernicke et al. investigated the effect of treatment margins for GBM
and concluded that treating GBM with limited margins has been achieved without compromising
overall survival or changing recurrence patterns [22]. As seen in Table 3, the expected survival varies
significantly depending on the tumor size and velocity. Therefore, reporting the effect of treatment
margins on survival without considering the individual tumor characteristics may lead to different
conclusions. We also note that increasing treatment margins without modifying the prescription dose
may increase normal tissue toxicity, which can also affect survival.
The estimations of survival time (based on Swanson's empirical observation that the modeled
tumor size correlates well with death [18]) indicate that personalizing the prescription scheme can
potentially increase the survival time by up to 10, 16, and 22 months for slow-, average-, and fast-move
tumors, respectively, even though we recognize that actual predictions of change in survival are
difficult given the complex physiology involved. The largest difference in survival time between the
personalized and standard prescription scheme was for the fast-move, small tumors. On the other
hand, the improvement of using a personalized scheme was the least for the fast-move, large tumors.
5. Conclusions
This study proposes a method to personalize a prescription scheme tailored to the individual
tumor characteristics, i.e., size and velocity as observed in serial MRIs. A different prescription scheme
leads to the least SF (i.e., maximum EUD) for different tumor characteristics, which may explain the
heterogeneous response to the same treatment among different patients. The results of this study show
the potential benefit of using a PI glioma model to personalize prescription variables based on the
individual tumor characteristics to improve clinical outcomes. Future work will include exploring
various mathematical models and investigating the effect of the model on the personalized prescription
schemes. For example, Eikenberry et al. used continuous diffusion-reaction equations to model the
behavior of proliferation and migrating tumor cells, and their interactions with chemorepellents
and the extracellular matrix, using stochastic transitions between migrating and proliferating glioma
cells [23].
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